SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-202813
Filing Date
2024-08-19
Accepted
2024-08-19 16:05:59
Documents
14
Period of Report
2024-08-14
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d882619d8k.htm   iXBRL 8-K 35162
2 EX-3.1 d882619dex31.htm EX-3.1 7510
  Complete submission text file 0001193125-24-202813.txt   177901

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA algs-20240814.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE algs-20240814_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE algs-20240814_pre.xml EX-101.PRE 12143
16 EXTRACTED XBRL INSTANCE DOCUMENT d882619d8k_htm.xml XML 3987
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39617 | Film No.: 241220452
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)